Electromed, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2854091087
USD
27.80
-0.15 (-0.54%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Electromed, Inc. stock-summary
stock-summary
Electromed, Inc.
Pharmaceuticals & Biotechnology
Electromed, Inc. develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company's products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others. As of June 30, 2016, the SmartVest System is available in two models: SV2100 and SQL. The SmartVest System consists of an inflatable therapy garment, a programmable air pulse generator and a single-hose, which delivers air pulses from the generator to the garment. The SmartVest SQL System is small, quiet and light, and offers generator programmability. The Company markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to healthcare providers, particularly those working in intensive care units. The Company sells its products to the home healthcare market for patients with chronic lung issues, including bronchiectasis, cystic fibrosis and neuromuscular disease.
Company Coordinates stock-summary
Company Details
500 6th Ave NW , NEW PRAGUE MN : 56071-1134
stock-summary
Tel: 1 952 75892991 212 8369614
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 13 Schemes (11.83%)

Foreign Institutions

Held by 28 Foreign Institutions (3.45%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Stephen Craney
Independent Chairman of the Board
Ms. Kathleen Skarvan
President, Chief Executive Officer, Director
Mr. Stan Erickson
Independent Director
Mr. Gregory Fluet
Independent Director
Ms. Lee Jones
Independent Director
Ms. Andrea Walsh
Independent Director
Dr. George Winn
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 208 Million (Micro Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.35

stock-summary
Return on Equity

17.78%

stock-summary
Price to Book

4.82